Skip to Main content Skip to Navigation
Journal articles

The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma: Bendamustine-rituximab in nodal MZL

Abstract : Primary nodal marginal zone lymphoma (NMZL) is a rare disease. There is no current consensus on how to treat it. The bendamustine plus rituximab (BR) regimen is effective for the treatment of follicular and other indolent lymphomas, but its efficacy in NMZL is not known. We analyzed the outcome of 14 patients diagnosed with NMZL (median age 67 years) who were treated with 375 mg/m2 of rituximab on day 1 and 90 mg/m2 of bendamustine on days 1 and 2. The overall and complete response rates were 93% and 71%, respectively. Major toxicity (grade 3/4 neutropenia) occurred in 5% of treatment courses. After a median follow-up of 22 months (range: 18-55), the overall survival and the free survival rates were 100% and 93%, respectively. None of the patients showing a complete or partial response developed secondary myelodysplastic syndrome/acute myeloid leukemia. Bendamustine plus rituximab was found to be an active and well-tolerated regimen leading to the rapid control of disease.
Complete list of metadatas

https://hal-univ-paris10.archives-ouvertes.fr/hal-01389962
Contributor : Alix Baugier de Materre <>
Submitted on : Sunday, October 30, 2016 - 10:57:53 PM
Last modification on : Thursday, November 21, 2019 - 1:39:12 AM

Identifiers

Citation

Laribi Kamel, Tempescul Adrien, Ghnaya Habib, Denizon Nathalie, Besançon Anne, et al.. The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma: Bendamustine-rituximab in nodal MZL. Hematological Oncology, Wiley, 2016, ⟨10.1002/hon.2334⟩. ⟨hal-01389962⟩

Share

Metrics

Record views

79